Drug allergy labeling and delabeling in the coronavirus disease 2019 era

At the time of this writing, April 7, 2020, more than 1.2 million people worldwide are infected and more than 68,000 have died because of coronavirus disease 2019 (COVID-19) induced by the novel severe acute respiratory syndrome coronavirus 2 infection, and this figure will surely multiply in the next few weeks according to Dr Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases. Severe acute respiratory syndrome coronavirus 2 uses angiotensin-converting enzyme-2 (ACE-2) (a type I transmembrane metallocarboxypeptidase) as its preferred entry receptor.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research